A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination with Durvalumab in Selected Advanced Solid Tumors

Project: Research

Project Description

NMA HREC Reference Number: HREC/16/MH/424
NMA SSA Reference Number: SSA/18/MonH/393
Monash Health Ref: RES-18-0000261X
StatusActive
Effective start/end date25/03/19 → 24/03/24
View all
View less

Keywords

  • clinical trial
  • advanced solid tumor
  • phase 1 study
  • treatment efficacy